Radionetics Oncology, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2023 | $54 M | No. 1 | $50 to $250 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Radionetics Oncology, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2023).
SEC Form D · Aug 2023
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Aug 2023
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Radionetics Oncology, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Ana Kusnetzow | Executive officer | Aug 2023 |
| Brett Ewald | Executive officer | Aug 2023 |
| Dan Estes | Executive officer | Aug 2023 |
| Istvan Molnar | Executive officer | Aug 2023 |
| Umesh Gangadharmath | Executive officer | Aug 2023 |
| Yunfei Zhu | Executive officer | Aug 2023 |
| Andrew Schwab | Director | Aug 2023 |
| Dan Estes | Director | Aug 2023 |
| Scott Struthers | Director | Aug 2023 |